Latest news with #RedcarePharmacy
Yahoo
03-08-2025
- Business
- Yahoo
Redcare Pharmacy Second Quarter 2025 Earnings: EPS: €0.46 (vs €0.21 loss in 2Q 2024)
Redcare Pharmacy (ETR:RDC) Second Quarter 2025 Results Key Financial Results Revenue: €709.2m (up 27% from 2Q 2024). Net income: €9.35m (up from €4.27m loss in 2Q 2024). Profit margin: 1.3% (up from net loss in 2Q 2024). The move to profitability was driven by higher revenue. EPS: €0.46 (up from €0.21 loss in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Redcare Pharmacy Earnings Insights Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 4.7% growth forecast for the Consumer Retailing industry in Europe. Performance of the market in Germany. The company's shares are down 14% from a week ago. Balance Sheet Analysis While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on Redcare Pharmacy's balance sheet. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
05-07-2025
- Business
- Business Insider
Kepler Capital Remains a Hold on Redcare Pharmacy (0RJT)
Kepler Capital analyst Sven Sauer maintained a Hold rating on Redcare Pharmacy on July 3 and set a price target of €130.00. The company's shares closed last Thursday at €95.35. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. According to TipRanks, Sauer is a 4-star analyst with an average return of 5.4% and a 43.91% success rate. Sauer covers the Industrials sector, focusing on stocks such as INDUS Holding, Heidelberger Druckmaschinen, and RENK Group AG. Currently, the analyst consensus on Redcare Pharmacy is a Moderate Buy with an average price target of €167.38. Based on Redcare Pharmacy's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €675.14 million and a GAAP net loss of €26.48 million. In comparison, last year the company earned a revenue of €531.32 million and had a GAAP net loss of €5.58 million Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of 0RJT in relation to earlier this year.
Business Insider
08-05-2025
- Business
- Business Insider
Warburg Research Keeps Their Buy Rating on Redcare Pharmacy (0RJT)
Warburg Research analyst Michael Heider maintained a Buy rating on Redcare Pharmacy (0RJT – Research Report) on May 6 and set a price target of €186.00. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Heider is a 3-star analyst with an average return of 3.0% and a 37.61% success rate. In addition to Warburg Research, Redcare Pharmacy also received a Buy from Berenberg Bank's Gerhard Orgonas in a report issued yesterday. However, on May 6, UBS maintained a Sell rating on Redcare Pharmacy (LSE: 0RJT). The company has a one-year high of €171.20 and a one-year low of €95.75. Currently, Redcare Pharmacy has an average volume of 10.07K. Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is neutral on the stock.
Yahoo
07-05-2025
- Business
- Yahoo
Redcare Pharmacy NV (SHPPF) Q1 2025 Earnings Call Highlights: Strong e-Rx Growth Drives 28% ...
Revenue: EUR717 million in Q1 2025, up 28% year-over-year. e-Rx Growth: Significant driver of growth, with RX in Germany increasing 191% year-over-year. EBITDA: Positive at 1.3% in Q1 2025, a 2%-point improvement from the previous quarter. Gross Profit Margin: Increased by 1%-point quarter-over-quarter. Active Customers: Increased by 4.6 million, reaching 13.1 million active customers. Net Promoter Score (NPS): 64, down from 70 in the previous year. Order Volume: 11.5 million orders in Q1 2025, with 89% being repeat orders. Cash Flow: Ended Q1 2025 with slightly above EUR180 million in cash. Convertible Bond: New convertible bond issued with a 1.75% annual coupon and a conversion price of EUR174. Guidance: Total sales growth expected to exceed 25% for 2025, with adjusted EBITDA between 2% and 2.5% for the full year. Release Date: May 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Redcare Pharmacy NV (SHPPF) reported a 28% increase in group sales, reaching EUR717 million in Q1 2025, driven by strong e-Rx growth. The company achieved a return to positive EBITDA, reaching 1.3% in Q1 2025, marking a 2%-point improvement from the previous quarter. Redcare Pharmacy NV (SHPPF) added 4.6 million active customers in Q1 2025, primarily driven by e-Rx, bringing the total to 13.1 million active customers. The company successfully executed two concurrent transactions, including the placement of a new convertible bond, securing financial stability for the coming years. Redcare Pharmacy NV (SHPPF) confirmed its full-year guidance for 2025, expecting total sales growth in excess of 25% and adjusted EBITDA between 2% and 2.5%. Negative Points The Net Promoter Score (NPS) decreased from 70 to 64, attributed to the influx of new customers and challenges in the RX and marketplace segments. Despite the positive growth, the gross profit margin remained stable year-over-year, indicating limited margin expansion. Marketing efficiency concerns were raised, with incremental marketing spend per revenue dollar increasing since last year. The company faces seasonality challenges, with market share fluctuations observed during holiday periods like Christmas and Easter. There is uncertainty regarding the impact of potential regulatory changes in RX remuneration, which could affect future financial performance. Q & A Highlights Q: Can you provide insights on the potential impact of the coalition paper's proposed RX remuneration increase on your business? A: Olaf Heinrich, CEO: We shouldn't speculate too much on the coalition agreement's outcome. Our guidance does not include any potential impact from this proposal. If it goes through, it might affect us by the end of this year or early next year, but we can't provide more details at this time.
Saba Yemen
11-03-2025
- Business
- Saba Yemen
European stocks stabilize amid investor caution after global technology sector decline
Brussels - Saba: European stocks stabilized during today's trading, Tuesday, in light of investors' caution following the sharp losses suffered by global technology companies' shares in the previous session, as a result of escalating concerns about the slowdown in economic growth in the United States and the possibility of sliding into recession due to escalating trade tensions. The pan-European Stoxx 600 index fell 0.07 percent by 08:14 GMT, after falling to its lowest level in about a month yesterday. On Wall Street, the Nasdaq, which includes major technology companies, fell 4 percent, reaching its lowest level in about six months, raising concerns about global markets. Travel and leisure stocks led the list of sectoral losses in Europe, down 1.6 percent, while healthcare stocks fell 1.2 percent. Banks also lost 0.9 percent, after benefiting recently from an improvement in the spending outlook in Germany. In contrast, Volkswagen shares rose 3.2 percent after announcing a positive forecast for a slightly higher operating profit margin in 2025. The auto and parts sector index rose 0.9 percent. On the other hand, Redcare Pharmacy shares rose by 12.3 percent, after the company revealed its annual results and announced optimistic expectations for its performance in 2025. Whatsapp Telegram Email Print more of (International)
